Us Bancorp \De\ Dbv Technologies S.A. Transaction History

Us Bancorp \De\

$77.3 Billion
Q3 2024

18 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 11, 2022	SELL	$1.22 - $1.77 $1,764 - $2,559	-1,446 Closed	0 $0
Q4 2021 Feb 11, 2022	SELL	$1.39 - $5.58 $144 - $580	-104 Reduced 6.71%	1,446 $2,000
Q3 2021 Nov 10, 2021	BUY	$4.71 - $5.92 $2,826 - $3,552	600 Added 63.16%	1,550 $7,000
Q2 2021 Aug 05, 2021	SELL	$5.32 - $6.53 $7,086 - $8,697	-1,332 Reduced 58.37%	950 $6,000
Q1 2021 Apr 28, 2021	SELL	$2.75 - $6.57 $25,558 - $61,061	-9,294 Reduced 80.29%	2,282 $12,000
Q4 2020 Feb 04, 2021	BUY	$1.38 - $3.01 $13,946 - $30,419	10,106 Added 687.48%	11,576 $30,000
Q3 2020 Nov 10, 2020	SELL	$1.58 - $4.77 $3,346 - $10,102	-2,118 Reduced 59.03%	1,470 $2,000
Q2 2020 Aug 07, 2020	BUY	$3.74 - $6.28 $6,455 - $10,839	1,726 Added 92.7%	3,588 $16,000
Q1 2020 May 13, 2020	SELL	$2.33 - $12.98 $4,284 - $23,870	-1,839 Reduced 49.69%	1,862 $7,000
Q4 2019 Feb 04, 2020	SELL	$6.75 - $11.15 $2,281 - $3,768	-338 Reduced 8.37%	3,701 $40,000
Q3 2019 Nov 08, 2019	BUY	$8.57 - $10.72 $2,896 - $3,623	338 Added 9.13%	4,039 $35,000
Q1 2019 May 08, 2019	SELL	$5.81 - $9.37 $3,979 - $6,418	-685 Reduced 15.62%	3,701 $29,000
Q4 2018 Feb 13, 2019	BUY	$5.75 - $21.85 $10,304 - $39,155	1,792 Added 69.08%	4,386 $28,000
Q3 2018 Nov 01, 2018	BUY	$16.81 - $24.58 $5,311 - $7,767	316 Added 13.87%	2,594 $59,000
Q2 2018 Aug 08, 2018	BUY	$18.6 - $24.94 $6,807 - $9,128	366 Added 19.14%	2,278 $44,000
Q1 2018 May 08, 2018	BUY	$20.86 - $26.6 $27,097 - $34,553	1,299 Added 211.91%	1,912 $44,000
Q4 2017 Feb 02, 2018	BUY	$20.9 - $49.36 $11,892 - $28,085	569 Added 1293.18%	613 $15,000
Q3 2017 Nov 13, 2017	BUY	$39.62 - $46.17 $1,743 - $2,031	44	44 $2,000

Others Institutions Holding DBVT

# of Institutions

Shares Held

3.2K

Call Options Held

Put Options Held

View Full List

About DBV Technologies S.A.

Ticker DBVT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 187,776,992
Market Cap $95.8M
Description
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...

More about DBVT

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Us Bancorp \De\, based on Form 13F filings with the SEC.

News

Stay updated on Us Bancorp \De\ with notifications on news.

Account